When was Alzheimer’s disease discovered? Alzheimer’s disease as we know it was first described by Dr. Alois Alzheimer, a German doctor, in 1906. He was
Sharing Our Perspectives
Alpha-synuclein is a neuronal protein that regulates trafficking and neurotransmitter release. Aggregation of alpha-synuclein is associated with the formation of lewy bodies, which are protein
Leukodystrophy Therapy: How is Gain Therapeutics Developing First-in-class treatment for Krabbe Disease
Krabbe disease is a devastating disease that belongs to the Leukodystrophy disease family. These diseases are characterized by defects in the myelin, an insulating layer
More of Our Perspectives
Gaucher Disease and Parkinson’s Disease are two distinctly different diseases in terms of their onset, symptoms, and prognosis. Despite these differences these diseases have one
Discovering treatments for patients that currently have no available disease-modifying options is the priority of Gain Therapeutics. Specifically, there is a large unmet need for
Enzyme Targeting: Over the last few years, diseases caused by dysfunctional or missing enzymes have been treated with a type of therapy called enzyme replacement
Gain Therapeutics targeting allosteric sites: Traditional small molecule drugs work by targeting an active binding site. Gain Therapeutics is focused on targeting allosteric binding sites,
Why is the AlphaFold DataBase exciting? DeepMind created the artificial intelligence system, AlphaFold, to predict the three-dimensional (3D) structure of thousands of proteins and compiled
What is DeepMind? Deepmind AlphaFold protein folding structure prediction: DeepMind is a company that combines a variety of disciplines to develop artificial intelligence (AI) technology
Genetic mutations are one of the most common causes of serious diseases. When genes are mutated it can affect the function of proteins which oftentimes
Designing therapeutics that target cellular proteins can be difficult due to the lack of specific binding sites or the potential for disrupting the normal protein
Parkinson’s Disease is among the most common degenerative brain disorders, affecting millions of people each year in the United States alone. We know that the
On September 30th, 2021 Gain Therapeutics presented at the Cantor Fitzgerald virtual global healthcare conference. Eric Richman, CEO and Manolo Bellotto, GM and President, sat
What is Gain Therapeutics Presenting at the MJFF 2021 Parkinson’s Disease Therapeutics Conference Webinar?
MJFF 2021 Conference: What is Gain Therapeutics Presenting at the MJFF 2021 Parkinson’s Disease Therapeutics Conference Webinar? This year due to the impact of the
Allosteric Binding Sites: One of the most prevalent issues in drug discovery and development is the difficulty to find novel drug targets. Majority of disease-causing
What makes Gain Therapeutics’ SEE-Tx Platform Unique when compared to Other Drug Discovery Platforms?
Gain Therapeutics’ SEE-Tx patented algorithm provides quantitative predictions of druggable binding hot spots based on changes in binding free energy (ΔG). No other company has
MJFF 2021 Conference: Everything about Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference
MJFF 2021 Conference: The Michael J. Fox. Foundation (MJFF) has held a Parkinson’s Therapeutics Conference annually every fall, starting from 2009. Due to the COVID-19
Gain Therapeutics’ physics-based screening platform is able to identify previously unknown binding pockets on well-validated protein targets by identifying cavities on the surface and in
Why is Gain Therapeutics’ collaboration with Zentalis Pharmaceuticals so important in addressing cancer?
On April 20th, 2021, Gain Therapeutics announced a multi-target drug discovery and development deal with Zentalis Pharmaceuticals to identify and address novel oncology targets. Gain
At Gain Therapeutics, we are uniquely positioned to capitalize on the AlphaFold project and
extend the scope of our existing technology.
Just last month, AlphaFold launched their Protein Structure Database, containing high-quality predicted structures of every protein in the human body.
For years, the neuroscience industry has been plagued by a high failure rate of drugs in the clinical stages.
“We were thrilled to complete our IPO in March on the Nasdaq Global Market Exchange,” stated Sal Calabrese, Chief Financial Officer of Gain.
Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted
BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 11, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing